logo

For the Inventor, By the Inventor

Osaka, Japan

Sumitomo Pharma Co., Ltd.


USPTO Granted Patents = 14



Forward Citations = 0

Loading Chart...
Loading Chart...

74 inventors (with patents filed for the assignee):

goldMedal Hitoshi Ban (4 out of 41 patents)

silverMedal Seiji Kamioka (4 out of 18 patents)

bronzeMedal Naoaki Shimada (3 out of 29 patents)

4.  Tomoyuki Tanaka (2 out of 17 patents)

5.  Hiroyuki Kitano (2 out of 12 patents)

6.  Petinka I Vlahova (2 out of 27 patents)

7.  Yoshiaki Isobe (2 out of 30 patents)

8.  Akihiko Arakawa (1 out of 5 patents)

9.  Kazuto Yamazaki (1 out of 5 patents)

10.  Atsushi Kuwahara (1 out of 13 patents)

11.  Hidefumi Yoshinaga (1 out of 19 patents)

12.  Jennifer Leigh Nelson (1 out of 25 patents)

13.  Satoshi Adachi (1 out of 9 patents)

14.  Tomohito Takita (1 out of 12 patents)

15.  Kaiji Fujiwara (1 out of 5 patents)


14 patents:

1. 12735430 - Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (2026-09-15),
2. 12673941 - TERTIARY AMIDE DERIVATIVES SUBSTITUTED WITH 4-MEMBERED RING STRUCTURE (2026-07-07),
3. 12662494 - Optically active bridged piperidine derivative (2026-06-23),
4. 12655154 - Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (2026-06-16),
5. 12636259 - Transdermal absorption preparation (2026-05-26),
6. 12629370 - Treatment of prostate cancer (2026-05-19),
7. 12624011 - Oxadiazole derivative (2026-05-12),
8. 12617779 - Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same (2026-05-05),
9. 12590063 - Phenol derivative (2026-03-31),
10. D1118970 - Dish (2026-03-17),
11. 12559487 - Crosslinked optically active secondary amine derivative (2026-02-24),
12. 12551447 - Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists (2026-02-17),
13. 12534475 - Bicyclic pyridine derivative (2026-01-27),
14. 12534442 - Benzisoxazole derivative (2026-01-27),
Company Overview
Sumitomo Pharma Co., Ltd. is a prominent pharmaceutical company based in Osaka, Japan, specializing in the research, development, manufacturing, and marketing of innovative medicines. The company focuses on various therapeutic areas, including central nervous system disorders, oncology, and infectious diseases. With a commitment to advancing healthcare, Sumitomo Pharma leverages cutting-edge research and technology to deliver effective solutions that address unmet medical needs, both in Japan and globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

14 Patents

#386 in Osaka

#3,580 in Japan

#42,249 in the World

Osaka, JP
Osaka, Japan

Sumitomo Pharma Co., Ltd.

Forward Citations = 0

74 inventors:

goldMedal Hitoshi Ban (4 out of 41 patents)

silverMedal Seiji Kamioka (4 out of 18 patents)

bronzeMedal Naoaki Shimada (3 out of 29 patents)

4.  Tomoyuki Tanaka (2 out of 17 patents)

5.  Hiroyuki Kitano (2 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sumitomo Pharma Co., Ltd.. Retrieved from https://idiyas.com/company/sumitomo-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…